No abstract available
Publication types
-
Clinical Trial, Phase I
-
Clinical Trial, Phase II
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Humanized / adverse effects
-
Antibodies, Monoclonal, Humanized / therapeutic use*
-
Antineoplastic Agents, Immunological / adverse effects
-
Antineoplastic Agents, Immunological / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Fatigue / chemically induced
-
Humans
-
Immunoconjugates / adverse effects
-
Immunoconjugates / therapeutic use*
-
Lymphoma, Non-Hodgkin / drug therapy*
-
Neoplasm Recurrence, Local / drug therapy*
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents, Immunological
-
Immunoconjugates
-
polatuzumab vedotin
-
obinutuzumab